Literature DB >> 15029983

Controlled trial of maintenance treatment of intravenous buprenorphine dependence.

J Ahmadi1, K Ahmadi.   

Abstract

BACKGROUND: Buprenorphine dependence is a relatively novel addiction. AIMS: To compare the treatment outcome in three groups over 12-weeks of treatment.
METHODS: Two hundred and four intravenous (i.v.)-buprenorphine-dependent patients were randomised into three groups. Subjects received 50 mg oral methadone tablet, or 5 mg sublingual buprenorphine tablet, or 50 mg oral naltrexone, and a weekly 30-minute clinical counselling session.
RESULTS: The majority (80%) had a history of opium or heroin dependency before they were introduced to i.v. buprenorphine. The main source of buprenorphine for misusers was street sale (91%). The mean duration of buprenorphine dependence was 1.9 years and the mean dose per day was 3.9 ampoules (1 ampoule contains 0.3 mg of buprenorphine in 1 ml). Overall 59% of the patients completed the 12-week study. Retention in the 50 mg methadone group was significantly better than the 5 mg dose buprenorphine group (p=0.001) and the 50 mg dose naltrexone group (p=0.000). Retention in the 5 mg buprenorphine group was significantly better than the 50 mg naltrexone dose group (p=0.000).
CONCLUSIONS: These results support the efficacy and safety of oral methadone and sublingual buprenorphine tablets for injection buprenorphine-dependent patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15029983     DOI: 10.1007/BF02915283

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  11 in total

1.  Injecting misuse of buprenorphine among French drug users.

Authors:  Y Obadia; V Perrin; I Feroni; D Vlahov; J P Moatti
Journal:  Addiction       Date:  2001-02       Impact factor: 6.526

2.  An exploratory study of buprenorphine use in Bangladesh: a note.

Authors:  S K Ahmed; N Ara
Journal:  Subst Use Misuse       Date:  2001-06       Impact factor: 2.164

3.  Abuse of buprenorphine.

Authors:  H B Rainey
Journal:  N Z Med J       Date:  1986-02-12

4.  Temgesic abuse.

Authors:  I Harper
Journal:  N Z Med J       Date:  1983-10-12

5.  A longitudinal study of male buprenorphine addicts attending an addiction clinic in India.

Authors:  D Basu; S K Mattoo; A Malhotra; N Gupta; R Malhotra
Journal:  Addiction       Date:  2000-09       Impact factor: 6.526

6.  A case of buprenorphine abuse.

Authors:  A J Quigley; D E Bredemeyer; S S Seow
Journal:  Med J Aust       Date:  1984-03-31       Impact factor: 7.738

7.  Buprenorphine abuse in India : an update.

Authors:  Y Sharma; S K Mattoo
Journal:  Indian J Psychiatry       Date:  1999-04       Impact factor: 1.759

8.  A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts.

Authors:  W K Bickel; M L Stitzer; G E Bigelow; I A Liebson; D R Jasinski; R E Johnson
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

9.  Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction.

Authors:  R E Johnson; E J Cone; J E Henningfield; P J Fudala
Journal:  Clin Pharmacol Ther       Date:  1989-09       Impact factor: 6.875

10.  Cases of buprenorphine abuse in India.

Authors:  R A Singh; S K Mattoo; A Malhotra; V K Varma
Journal:  Acta Psychiatr Scand       Date:  1992-07       Impact factor: 6.392

View more
  6 in total

1.  Opiate withdrawal syndrome in buprenorphine abusers admitted to a rehabilitation center in Tunisia.

Authors:  Ines Derbel; Asma Ghorbel; Férièle Messadi Akrout; Abdelmajid Zahaf
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

Review 2.  Opioid agonist treatment for people who are dependent on pharmaceutical opioids.

Authors:  Suzanne Nielsen; Wai Chung Tse; Briony Larance
Journal:  Cochrane Database Syst Rev       Date:  2022-09-05

3.  Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.

Authors:  R Douglas Bruce; Sumathi Govindasamy; Laurie Sylla; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

Review 4.  Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.

Authors:  Nikki Bozinoff; Vitor Tardelli; Dafna Sara Rubin-Kahana; Bernard Le Foll
Journal:  Harm Reduct J       Date:  2022-10-13

Review 5.  Impact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysis.

Authors:  Brittany B Dennis; Monica Bawor; Leen Naji; Carol K Chan; Jaymie Varenbut; James Paul; Michael Varenbut; Jeff Daiter; Carolyn Plater; Guillaume Pare; David C Marsh; Andrew Worster; Dipika Desai; Lehana Thabane; Zainab Samaan
Journal:  Subst Abuse       Date:  2015-09-10

6.  A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder.

Authors:  Brittany B Dennis; Nitika Sanger; Monica Bawor; Leen Naji; Carolyn Plater; Andrew Worster; Julia Woo; Anuja Bhalerao; Natasha Baptist-Mohseni; Alannah Hillmer; Danielle Rice; Kim Corace; Brian Hutton; Peter Tugwell; Lehana Thabane; Zainab Samaan
Journal:  Trials       Date:  2020-01-06       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.